STRIDE Trial: Effects of Semaglutide in Patie...

Among patients with symptomatic nonobstructive hypertrophic cardiomyopathy (HCM), treatment with aficamten resulted in significantly greater improvements in exercise capacity and quality of life compared with placebo over 36 weeks. The ACACIA-HCM findings offer promising news for ...  Show more

The PRESC1SE-MI trial evaluated whether an accelerated diagnostic pathway for suspected myocardial infarction could improve Emergency Department efficiency without compromising safety. Compared with standard care, the accelerated strategy demonstrated similar safety but did not r ...  Show more

Semaglutide has recently been shown to induce clinically significant weight loss in patients with obesity that is sustained for as long as the drug is given. Tom Wadden, PhD, from the University of Pennsylvania, discusses results from the series of recent STEP trials and how they ...  Show more

In this episode, we will discuss all things peripheral arterial disease – definitions, staging, clinical presentation, risk factors, goals of therapy, and guideline-directed medication therapy recommendations including the newest evidence for the use of DOACs. Key Concepts Addres ...  Show more

On this podcast episode, I discuss the pharmacology, adverse effects, and drug interactions of semaglutide. Semaglutide has two primary uses: Type 2 diabetes and Weight Management – the dosing varies depending upon the indication. When using semaglutide, pay attention to GI adver ...  Show more

Dr. Peter Quiros joins host Dr. Amanda Redfern to discuss the recent JAMA Ophthalmology article "The Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide," the first study to report a possible association between semaglutide (Wegovy, Ozempic, ...  Show more